MENU
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • For Media Inquiries
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • For Media Inquiries
  • Contact Us
  • 日本語
  • English
  • About Us
  • Blog
  • Series
  • Category
  • For Media Inquiries
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • For Media Inquiries
  • Contact Us
  • 日本語
  • English
  1. Home
  2. M&A、

M&A、– tag –

  • Pharma & Biotech News

    JPM2026 Key Topics Series Part 2: Why Mega-M&A Didn’t Show Up — Yet Capital and Deals Still Moved

    One of the defining “feelings” at JPM2026 was that the conference was crowded and energetic—yet true mega-M&A headlines were scarce. One of the defining “feelings” at JPM2026 was that the conference was crowded and energetic—yet true...
    2026-01-22
  • Pharma & Biotech News

    JPM2026 Key Topics Series Part 1: Obesity & Metabolic (GLP-1) — The Battle Has Moved to Execution

    At JPM2026, obesity and metabolic disease (GLP-1) remained the gravitational center of the conference. At JPM2026, obesity and metabolic disease (GLP-1) remained the gravitational center of the conference. Yet the most decisive conversat...
    2026-01-21
1
  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語

© Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~.

  • Menu
  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語